SXTP - 60 Degrees Pharmaceuticals Inc. Market Cap to Sales Volume

60 Degrees Pharmaceuticals (SXTP) commercializes treatments for tropical infections to protect military personnel and tourists. The price-to-sales ratio trend on the GURU.Markets chart shows that the value is holding at 1.20. Government contracts and clinics ensure stable demand. The business relies on a high-leverage patent model, utilizing distributors to scale without increasing headcount.

60 Degrees Pharmaceuticals (SXTP): Price-to-Revenue Ratio from 04/03/2024 to 11/14/2026

Metric breakdowns and analytics for 60 Degrees Pharmaceuticals (SXTP)

- market price and analyst price targets:

Stock Quotes 60degreespharma.com|SXTP - Consensus Target

- market capitalization statistics:

Market Value 60 Degrees Pharma|SXTP - Enterprise Value

- book capitalization information:

Net Assets per Share 60 Degrees Pharmaceuticals|SXTP - Company Book Value|Market-to-Book Ratio 60degreespharma.com|SXTP - Aggregate Company Assets

- debt obligations and liquidity statistics:

Debt to Equity Ratio 60 Degrees Pharmaceuticals|SXTP - Long-Term Debt to Equity|Short-Term Debt to Capital Coefficient 60degreespharma.com|SXTP - Company Aggregate Indebtedness|Debt to Book Capital 60 Degrees Pharma|SXTP - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings 60 Degrees Pharmaceuticals|Immediate Liquidity Ratio 60degreespharma.com

- net income and valuation ratios data:

SXTP - Net Profit|Expected Net Profit 60 Degrees Pharmaceuticals|SXTP - P/E Multiple|Forward Price to Earnings Multiple 60degreespharma.com|SXTP - Price/Earnings to Growth Ratio|Business Value to Operating Income Before Depreciation 60 Degrees Pharma|SXTP - Operating profit EBITDA|Net earnings per one share for the last twelve months 60 Degrees Pharmaceuticals|SXTP - Net earnings per share (EPS TTM)|Earnings per share growth in annualized terms for the last twelve months 60degreespharma.com|SXTP - Earnings per share growth in current year|Consensus forecast of earnings per share growth for next year 60 Degrees Pharmaceuticals

- total revenue and sales volume data:

SXTP - Company Sales|Company Future Revenue 60degreespharma.com|SXTP - Price-to-Revenue Ratio|Future Price to Revenue 60 Degrees Pharma

Initial company analysis:60 Degrees Pharmaceuticals Inc.

Manufactured products of 60 Degrees Pharmaceuticals Inc.

Due to its monopoly position in the antimalarial segment and the inelastic demand for Arakoda, 60 Degrees Pharmaceuticals (SXTP) possesses significant pricing power. This enterprise value-to-revenue multiple correlates market capitalization with annual turnover, allowing investors to track business valuation phases in real-time and promptly identify correction risks during extreme metric deviations.

Who 60 Degrees Pharmaceuticals competes with

Market Cap to Revenue summittxinc.com SMMT|Moderna - Market Cap to Revenue|Market Cap to Sales Volume PCVX (Vaxcyte Inc)|Tarsus Pharma - P/S Multiple|Price-to-Revenue Coefficient CorMedix Therapeutics CRMD|Seres Therapeutics (MCRB) - Price-to-Revenue Ratio|Price to Sales sperotherapeutics.com (SPRO)|Price-to-Revenue Ratio SCYNEXIS Inc|Market Cap to Revenue Ratio ANTX (AN2 Bio)|Price-to-Revenue Ratio PolyPid Ltd. (PYPD)|Price-to-Revenue Coefficient YS Biopharma Co., Ltd.|Iterum Therapeutics (ITRM) - Price-to-Sales Ratio|Market Cap to Sales Volume PHGE (BiomX Inc)|SNGX: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio OGEN (oragenics.com)|OPGN: P/S Multiple